prof. dr. H.M. (Helena) Verkooijen
- Clinical Trial Office
- Julius Center Research Program Cancer
Research Programs
Biography
Biography
Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.
Leader (PI) of several international (H2020) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member.
Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).
I lead two international consortia (one H2020 European, one transatlantic) and collaborate closely with (international) academic and industry partners. I am regularly invited as speaker at international conferences, educational sessions and consortium meetings, and as panelist at meetings/debates of professional organizations. I serve as a member in several scientific advisory boards and expert committees.
I am Strategic Advisor for 'NTvG Gezonde Zorg', a campaign of the Dutch Journal of Medicine (Nederlands Tijdschrift voor Geneeskunde). This campaign contributes to ensuring sustainability and affordability of health care in the Netherlands by exposing the harms of medicalisation (overdiagnosis and overtreatment) and explicitly demonstrating the power of (primary) prevention.
Side Activities
- Strategic Advisor 'NTvG Gezonde Zorg'
- Board Member Dutch Breast Cancer Research Group (Borstkanker Onderzoek Groep, BOOG)
- Member Scientific Advisory Board Dutch Expert Centre for Screening
- Board Member J.M. Fentener van Vlissingen Fonds
- Member Scientific Advisory Board Dutch Prospective Colorectal Cancer Cohort (PLCRC)
- Member Expert Committee Value-Based Health Care Breast Cancer (NFU)
Research Output (298)
Bartels Marcia M T J, Verpalen Inez M, Ferrer Cyril J, Slotman Derk J, Phernambucq Erik C J, Verhoeff Joost J C, Eppinga Wietse S C, Braat Manon N G J A, van den Hoed Rolf D, van 't Veer-Ten Kate Miranda, de Boer Erwin, Naber Harry R, Nijholt Ingrid M, Bartels Lambertus W, Bos Clemens, Moonen Chrit T W, Boomsma Martijn F, Verkooijen Helena M mrt 2021, In: Clinical and translational radiation oncology. 27 , p. 57-63 7 p.
Bartels M M T J, Gal R, van der Velden J M, Verhoeff J J C, Verlaan J J, Verkooijen H M 25 feb 2021, In: Clinical & Experimental Metastasis. 38 , p. 209-217 9 p.
Bargon Claudia A, Batenburg Marilot C T, van Stam Lilianne E, Mink van der Molen Dieuwke R, van Dam Iris E, van der Leij Femke, Baas Inge O, Ernst Miranda F, Maarse Wiesje, Vermulst Nieke, Schoenmaeckers Ernst J P, van Dalen Thijs, Bijlsma Rhodé M, Young-Afat Danny A, Doeksen Annemiek, Verkooijen Helena M feb 2021, In: JNCI cancer spectrum. 5 , p. 1-11
Vasmel Jeanine E, Vreuls Celien Ph, Manson Quirine F, Charaghvandi Ramona K, van Gorp Joost, van Leeuwen Am Gijs, van Diest Paul J, Verkooijen Helena M, Desiree van den Bongard H J G 15 dec 2020, In: International Journal of Radiation Oncology Biology Physics. 109 , p. 1325-1331 7 p.
Pielkenrood Bart J, van der Velden Joanne M, van der Linden Yvette M, M T Bartels Marcia, Kasperts Nicolien, Verhoeff Joost J C, Eppinga Wietse S C, Gal Roxanne, Verlaan Jorrit J, Verkooijen H M Lenny 14 dec 2020, In: International Journal of Radiation Oncology Biology Physics. 110 , p. 358-367 10 p.
Gal R, Oostinga D, Wessels H, Verlaan J J, Charest-Morin R, Fisher C G, Verkooijen H M, Versteeg A L 9 dec 2020, In: BMC Cancer. 20
Batenburg M C T, van den Bongard H J G D, Kleynen C E, Maarse W, Witkamp A, Ernst M, Doeksen A, van Dalen T, Sier M, Schoenmaeckers E J P, Baas I O, Verkooijen H M 27 nov 2020, In: Trials. 21
Jacobs D., Charaghvandi R. K., Horeweg N., Maduro J. H., II, Speijer G., Roeloffzen E. M. A., Fisscher U., Mast M., Bantema-Joppe E. J., Petoukhova A., van den Bongard H. J. G. D., Koper P., Crijns A. P. G., Marijnen C., Verkooijen H. 1 nov 2020, In: International Journal of Radiation Oncology Biology Physics. 108 , p. E25-E26
Young-Afat Danny A., Gal Roxanne, Gerlich Sophie, Burbach Johannes P.M., van der Velden Joanne M., van den Bongard Desireé H.J.G., Intven Martijn P.W., Kasperts Nicolien, May Anne M., van der Graaf Rieke, van Gils Carla H., Verkooijen Helena M. 31 okt 2020, In: Journal of Clinical Epidemiology. 130 , p. 135-142 8 p.
Gal R., van Velzen S. G., Emaus M. J., van den Bongard D. H., Gregorowitsch M. L., Blezer E. L., Sofie G., Lessmann N., Sattler M. G., Hooning M. J., Teske A. J., Penninkhof J. J., Meijer H., Pignol J. P., Verloop J., Išgum I., Verkooijen H. M., okt 2020, In: European Journal of Cancer. 138 , p. S6